Dr Andrew J Mays, MD in Birmingham, AL - Medicare Ophthalmology

Dr Andrew J Mays, MD is a medicare enrolled "Ophthalmology" physician in Birmingham, Alabama. He went to University Of Alabama School Of Medicine and graduated in 1991 and has 33 years of diverse experience with area of expertise as Ophthalmology. He is a member of the group practice University Of Alabama Ophthalmology Services Foundation and his current practice location is 700 18th St S, Suite 601, Birmingham, Alabama. You can reach out to his office (for appointments etc.) via phone at (205) 325-8621.

Dr Andrew J Mays is licensed to practice in Alabama (license number 00016547) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1699784678.

Contact Information

	Dr Andrew J Mays, MD
	700 18th St S, Suite 601, Birmingham, AL 35233-1856
	(205) 325-8621
	(205) 297-0374

Physician's Profile

Full Name	Dr Andrew J Mays
Gender	Male
Speciality	Ophthalmology
Experience	33 Years
Location	700 18th St S, Birmingham, Alabama
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Andrew J Mays attended and graduated from University Of Alabama School Of Medicine in 1991

NPI Data:

NPI Number: 1699784678
Provider Enumeration Date: 08/07/2006
Last Update Date: 08/18/2020

Medicare PECOS Information:

PECOS PAC ID: 0749228138
Enrollment ID: I20080129000251

Medical Identifiers

Medical identifiers for Dr Andrew J Mays such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1699784678	NPI	-	NPPES
000036733	Medicaid	AL
631106237	Other	AL	TAX I.D.

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207W00000X	Ophthalmology	00016547 (Alabama)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Callahan Eye Hospital	Birmingham, AL	Hospital

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
University Of Alabama Ophthalmology Services Foundation	9234023417	35

News Archive

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

Cultured stem cells and bioengineered skin used to successfully treat scleroderma

Scleroderma is an autoimmune disease that leads to thickening and severe scarring of skin as well as thickening and failure of internal organs, including the lungs, heart, kidneys and intestines.

Portugal's first major forensic case attests the importance of toxicological analysis

Announcing a new article publication for Forensic Sciences Research journal. In this review article the author Ricardo Jorge Dinis-Oliveira of the University Institute of Health Sciences (IUCS)-CESPU, Gandra, Portugal continues a three-part investigation of the "Crime of Flores Street" one of the most famous cases of poisoning which occurred in Portugal in the late 19th century.

Targeting brain protein may lead to new therapeutic approaches for neurodegenerative disorders

Neurological disorders are the number one cause of disability in the world, leading to seven million deaths each year. Yet few treatments exist for these diseases, which progressively diminish a person's ability to move and think.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Andrew J Mays allows following entities to bill medicare on his behalf.

Entity Name	University Of Alabama Ophthalmology Services Foundation
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1265485999 PECOS PAC ID: 9234023417 Enrollment ID: O20040210000034

News Archive

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Cultured stem cells and bioengineered skin used to successfully treat scleroderma

Scleroderma is an autoimmune disease that leads to thickening and severe scarring of skin as well as thickening and failure of internal organs, including the lungs, heart, kidneys and intestines.

Portugal's first major forensic case attests the importance of toxicological analysis

Targeting brain protein may lead to new therapeutic approaches for neurodegenerative disorders

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Andrew J Mays is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Andrew J Mays, MD 700 18th St S, Suite 601, Birmingham, AL 35233-1856 Ph: (205) 325-8620	Dr Andrew J Mays, MD 700 18th St S, Suite 601, Birmingham, AL 35233-1856 Ph: (205) 325-8621

News Archive

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Cultured stem cells and bioengineered skin used to successfully treat scleroderma

Scleroderma is an autoimmune disease that leads to thickening and severe scarring of skin as well as thickening and failure of internal organs, including the lungs, heart, kidneys and intestines.

Portugal's first major forensic case attests the importance of toxicological analysis

Targeting brain protein may lead to new therapeutic approaches for neurodegenerative disorders

Ophthalmology Doctors in Birmingham, AL

Carol E Rosenstiel, OD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 700 18th St S Ste 200, Birmingham, AL 35233 Phone: 205-325-8620
Alex J Wright, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 1720 University Blvd, Birmingham, AL 35233 Phone: 205-325-8100 Fax: 205-325-8547
Elmar M Lawaczeck, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1009 Montgomery Hwy, Suite 200, Birmingham, AL 35216 Phone: 205-397-9400 Fax: 205-397-9455
Matthew Henry Oltmanns, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2208 University Blvd Ste 101, Birmingham, AL 35233 Phone: 205-933-2625 Fax: 205-558-2553
Harold Augustus Helms, MD, PHD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1100 23rd St S, Ste 100, Birmingham, AL 35205 Phone: 205-933-2020 Fax: 205-933-0908
Krupa Hasmukh Patel, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 700 18th St S Ste 601, Birmingham, AL 35233 Phone: 205-325-8620
William Charles Gambla, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 700 18th St S Ste 601, Birmingham, AL 35233 Phone: 205-996-8660

Dr Andrew J Mays, MD - Medicare Ophthalmology in Birmingham, AL

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medical Facilities Affiliation

Group Practice Association

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Cultured stem cells and bioengineered skin used to successfully treat scleroderma

Portugal's first major forensic case attests the importance of toxicological analysis

Targeting brain protein may lead to new therapeutic approaches for neurodegenerative disorders

Medicare Reassignments

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Cultured stem cells and bioengineered skin used to successfully treat scleroderma

Portugal's first major forensic case attests the importance of toxicological analysis

Targeting brain protein may lead to new therapeutic approaches for neurodegenerative disorders

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Cultured stem cells and bioengineered skin used to successfully treat scleroderma

Portugal's first major forensic case attests the importance of toxicological analysis

Targeting brain protein may lead to new therapeutic approaches for neurodegenerative disorders

Ophthalmology Doctors in Birmingham, AL